Clinical effect of 3D regimen (paritaprevir/ritonavir/ombitasvir combined with dasabuvir) in treatment-naive patients with genotype 1b chronic hepatitis C

Objective To investigate the clinical effect of 3D regimen (paritaprevir/ritonavir/ombitasvir combined with dasabuvir) in treatment-naive patients with genotype 1b chronic hepatitis C. Methods A total of 10 patients with genotype 1b chronic hepatitis C who were treated for the first time in Department of Infectious Diseases in our hospital from September 2015 to April 2016 were enrolled. All patients were treated with 3D regimen for 12 weeks and followed up for 24 weeks after treatment. Sustained virologic response at 12 and 24 weeks (SVR12 and SVR24) was observed, and the changes in biochemical parameters and the incidence of adverse events were monitored. An analysis of variance was used for comparison of continuous data between groups. Results After 2 weeks of treatment, 70% of all patients achieved an HCV RNA level reduced to below the detection level, and after 12 weeks of treatment, HCV RNA was not detected in any patient, resulting in a biochemical response rate of 100%. Both SVR12 and SVR24 were 100%. There were significant reductions in the levels of alanine aminotransferase, aspartate aminotransferase, and the inflammatory marker interferon-inducible protein 10 after treatment (F =20. 15, 10. 83, and 13. 67, all P < 0. 05) . The most common adverse events were weakness and headache and no serious adverse events were observed. Conclusion In treatment-naive patients with genotype 1b chronic hepatitis C, 3D regimen achieves high SVR rate and biochemical response rate, improves patients' liver function, and has good safety.